Experimental combo for tough-to-treat colon cancer pulled before starting
NCT ID NCT06557278
First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 20 times
Summary
This study was designed for people with advanced colorectal cancer that had stopped responding to standard treatments. It aimed to test a new combination of two immunotherapy drugs: AlloStim and an anti-PDL1 checkpoint inhibitor. The goal was to see if this combination could shrink tumors or help patients live longer. However, the study was withdrawn before any participants were enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hirschfield Oncology Center
Brooklyn, New York, 11206, United States
-
Mt. Sinai Comprehensive Cancer Center
Miami Beach, Florida, 33140, United States
-
New York Cancer and Blood Specialists
Shirley, New York, 11967, United States
Conditions
Explore the condition pages connected to this study.